MedTrace Logo

Gripwise® Versus JAMAR®

NCT05060874 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 348

Last updated 2021-11-30

No results posted yet for this study

Summary

It is recommended to screen ageing patients for sarcopenia, due to the increased risk of morbimortality if detected positive. According to the consensus of the European Working Group on Sarcopenia in Older People, the diagnosis of sarcopenia is based, among other things, on grip strength measurement.

Our study will compare the performance of the new GRIPWISE digital device with the mechanical dynamometer JAMAR, the gold standard currently used to assess the grip strength. We propose to evaluate it in an elderly hospitalized population where the prevalence of sarcopenia is likely to be high due to the high prevalence of various chronic illness, notably oncological and cardiological ones.

This cross-sectional study will include 348 patients.

Conditions

  • Age-Related Sarcopenia

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Bérengère Beauplet, MD · Caen UH

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2021-09-01
Completion
2021-11-18

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05060874 on ClinicalTrials.gov